Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arch Therapeutics ( (ARTH) ) just unveiled an announcement.
On February 3, 2025, Arch Therapeutics, a company in the medical technology sector, experienced a significant leadership change. Michael S. Abrams resigned from his roles as Chief Financial Officer and Treasurer, with immediate effect, and waived any claims to financial obligations under his contract. Concurrently, Terrence W. Norchi, the current CEO, Chairman, President, and Secretary, has been appointed to assume the additional responsibilities of Principal Accounting Officer and Treasurer.
More about Arch Therapeutics
YTD Price Performance: 20.59%
Average Trading Volume: 8,164
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $913.5K
For a thorough assessment of ARTH stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue